Carboplatin in Patients With Progressive Gliomas
Phase 2
Completed
- Conditions
- Brain and Central Nervous System Tumors
- Registration Number
- NCT00002749
- Lead Sponsor
- Duke University
- Brief Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of carboplatin in patients with progressive glioma.
- Detailed Description
OBJECTIVES: I. Assess the response to carboplatin (CBDCA) in patients with progressive low-grade gliomas. II. Assess the activity of CBDCA in stabilizing the growth of these tumors.
OUTLINE: Single-Agent Chemotherapy. Carboplatin, CBDCA, NSC-241240.
PROJECTED ACCRUAL: A total of 25 evaluable patients will be entered if there is at least 1 response in the first 9 patients.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
Duke Comprehensive Cancer Center
🇺🇸Durham, North Carolina, United States
Hopital Sainte Justine
🇨🇦Montreal, Quebec, Canada
Duke Comprehensive Cancer Center🇺🇸Durham, North Carolina, United States